Css LLC Il Has $1.10 Million Stock Position in GSK plc (NYSE:GSK)

CSS LLC IL raised its stake in shares of GSK plc (NYSE:GSK - Free Report) by 150.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,520 shares of the pharmaceutical company's stock after buying an additional 19,520 shares during the period. CSS LLC IL's holdings in GSK were worth $1,100,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Continuum Advisory LLC raised its holdings in GSK by 14.0% during the fourth quarter. Continuum Advisory LLC now owns 12,080 shares of the pharmaceutical company's stock valued at $409,000 after buying an additional 1,481 shares in the last quarter. Voloridge Investment Management LLC boosted its holdings in shares of GSK by 1,360.4% during the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after buying an additional 2,016,795 shares during the period. Waverly Advisors LLC boosted its holdings in shares of GSK by 113.2% during the 4th quarter. Waverly Advisors LLC now owns 13,233 shares of the pharmaceutical company's stock worth $448,000 after buying an additional 7,025 shares during the period. Woodline Partners LP bought a new stake in shares of GSK during the 4th quarter worth $36,665,000. Finally, Vestal Point Capital LP boosted its holdings in shares of GSK by 233.3% during the 4th quarter. Vestal Point Capital LP now owns 1,000,000 shares of the pharmaceutical company's stock worth $33,820,000 after buying an additional 700,000 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Performance

Shares of GSK stock traded down $0.23 during trading on Friday, reaching $38.70. The company's stock had a trading volume of 3,666,936 shares, compared to its average volume of 4,836,207. GSK plc has a one year low of $31.72 and a one year high of $45.01. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a market cap of $79.84 billion, a price-to-earnings ratio of 24.34, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The business's fifty day moving average price is $37.27 and its 200-day moving average price is $36.03.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same period in the previous year, the company posted $0.43 earnings per share. The company's quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a yield of 4.36%. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. GSK's payout ratio is currently 86.60%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GSK shares. BNP Paribas assumed coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.